Neurocrine Biosciences (NBIX)
Health Care · biopharmaceuticals · NASDAQ
A neuroscience-focused biopharmaceutical company commercializing specialized treatments for neurological and endocrine disorders while advancing a diverse pipeline of therapeutic modalities.
What Neurocrine Biosciences does
Neurocrine Biosciences is a neuroscience-focused biopharmaceutical company dedicated to developing treatments for neurological, psychiatric, endocrine, and immunological disorders. The company's commercial portfolio features FDA-approved therapies for conditions such as tardive dyskinesia, Huntington's disease chorea, congenital adrenal hyperplasia, and hyperphagia in Prader-Willi syndrome. It also maintains a diverse clinical pipeline spanning small molecules, biologics, and gene therapies.
Themes: neuroscience therapeutics, rare disease treatments, tardive dyskinesia, congenital adrenal hyperplasia, Prader-Willi syndrome, Huntington's disease chorea, drug development
Fundamentals
- Price$152.57 as of 2026-08-21 close
- Market cap$15.5B as of 2026-08-21
- 1-year return+12.8% 2025-08-21 close $135.28 → 2026-08-21 close $152.57
- P/E21.99 as of 2026-08-24
- Net margin+20.9% as of 2026-08-24
- Gross margin+98.0% as of 2026-08-24
- ROE+21.1% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Revenue growth (YoY)+34.4% as of 2026-08-24
- Revenue CAGR (3y)+24.3% SEC XBRL
- Beta0.39 as of 2026-08-24
- Last reported earnings2026-07-30 SEC EDGAR Form 8-K (Item 2.02)
How NBIX compares in its sector
- price-to-earnings ratiomiddle range 203 covered Health Care peers, as of 2026-08-24
- net profit margintop 25% 504 covered Health Care peers, as of 2026-08-24
- operating margintop 25% 504 covered Health Care peers, as of 2026-08-24
- gross margintop 10% 384 covered Health Care peers, as of 2026-08-24
- return on equitytop 25% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)top 25% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
NBIX is not currently in any published Top 10 list. Its scores are below.
Long-term score
Not scored for the long-term list: no shareholder return data.
Short-term score
38.7 #1444 of 1,704 scored · #214 of 240 in Health Care
Volume and participation 62nd: trading volume is about normal versus its 30-day average; catalysts 51st: open-market insider buys in 90 days 38, the analyst consensus rating is unchanged since the prior reading; weakest is trend 21st: a strong downtrend, with sellers in control.
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
How Neurocrine Biosciences looks technically
Neurocrine Biosciences (NBIX) is trading 3.9% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 54 trading days ago — a "golden cross", a bullish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 32, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 37, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 7 trading days ago. It is 18.0% below its highest point of the past year.
Trend
7
| Distance from the 200-day | it is trading 3.9% above its 200-day average, the long-term trend line — a longer-term uptrend | +3.9% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $167.01 | $167.01 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $146.85 | $146.85 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 7 calendar days ago — the swings before that are what the structure reading is measured on | 7 sessions |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 54 trading days ago — a "golden cross", a bullish long-term signal | 54 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 32, with sellers in control | 31.8 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 37, neither overbought (above 70) nor oversold (below 30) | 36.7 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($148.78 to $169.01) — its "stochastic" reading is 19 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 18.8 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 16 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $186.12 | $186.12 |
|---|---|---|
| From the 52-week high | it is 18.0% below its 52-week high (its highest price of the past year) | -18.0% |
| Above the 52-week low | it is 24.9% above its 52-week low (its lowest price of the past year) | +24.9% |
| Below the 52-week high | it is 18.0% below its highest point of the past year | 18.0% |
| Since a 20-day breakout | it made a new 20-day low about 7 trading days ago | 7 sessions |
| Since a 55-day breakout | it made a new 55-day low about 7 trading days ago | 7 sessions |
| All-time high | its highest closing price on record is $186.12 (set on 2026-07-30) | $186.12 |
| Given back of the 52-week move | over the past year its closes ranged ($123.10 to $185.50), and it has given back around half of its rise from last year’s low — 53% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $144.94 to $146.94. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 52.8% |
| From the all-time high | it is 18.0% below its all-time high | -18.0% |
| Nearest price level | it is trading 1.0% below a resistance level at $154.13 — a price it turned at four times since 2025-01-30, most recently on 2026-06-16. Since 2024-08-21 it has 10 such levels below the current price and 3 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +1.0% |
| All-time low | its lowest closing price on record is $1.94 (set on 2009-11-30) | $1.94 |
| Above the all-time low | it is 7764.4% above its all-time low | +7,764% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 91% of the past ~6 months) | 91st percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $4.87 between its high and its low — about 3.2% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $4.87 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $142.53 and $184.07 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $142.53 – $163.30 – $184.07 |
| Typical daily range (% of price) | its price moves about 3.2% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.2% |
| Stretch from the 200-day average | it is trading 1.2 daily ranges above its 200-day average price (3.9% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.2 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.93× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 0.7% since the prior reading | -0.7% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Price gaps
1
| Gap at the open | it opened on 2026-08-21 0.1% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.1% |
|---|
Price streaks
1
| Closing streak | it has closed lower 2 sessions in a row, a -1.91% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 2 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 17.1 percentage points (the stock lost 14.8% while the market gained 2.3%) | -17.1% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 5.0 percentage points (the stock lost 1.9% while the market gained 3.1%) | -5.0% |
| vs market, 6 months | over the past 6 months this stock beat the market by 7.5 percentage points (the stock gained 18.6% while the market gained 11.1%) | +7.5% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 7.7 percentage points (the stock gained 12.8% while the market gained 20.5%) | -7.7% |
Signal agreement
2
| Bullish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, outperforming the market over 6 months, near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 4 of 9 |
|---|---|---|
| Bearish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bearish state: a strong downtrend, with sellers in control, MACD momentum is negative, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 3 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 0.8% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 11.7% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -0.8% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 4% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $147.38 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | +3.5% |
|---|---|---|
| Vs the average paid since it last reported | the price is 6% below the average price paid since it last reported on 2026-07-30 (its 8-K), so the typical buyer over that stretch is under water. That average is $161.78 — a volume-weighted average of daily closes over 17 sessions, not a true tick-by-tick VWAP. | -5.7% |
Price levels it has turned at before
NBIX last closed at $152.57 on 2026-08-21. Since 2024-08-21 it has turned at 10 prices below its last close and 3 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $154.13 | Resistance | 1.0% above the last close | turned there four times · 2025-01-30 to 2026-06-16 |
| $148.92 | Support | 2.4% below the last close | turned there three times · 2025-09-24 to 2026-08-14 |
| $161.28 | Resistance | 5.7% above the last close | turned there twice · 2025-12-08 to 2026-05-14 |
| $141.91 | Support | 7.0% below the last close | turned there twice · 2025-12-19 to 2026-02-10 |
| $138.71 | Support | 9.1% below the last close | turned there six times · 2024-12-18 to 2026-01-23 |
| $169.29 | Resistance | 11.0% above the last close | turned there twice · 2026-06-04 to 2026-07-16 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · beating the market · At the bottom of its 14-day range (stochastic below 20) · Under water since its last earnings report (below the anchored VWAP) · Trading below the Ichimoku cloud · Near a resistance level (pressing into a price that has capped it before) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.44 mean, 1=Strong Buy…5=Strong Sell) — 27 analysts
- Mean price target$211.57 range $165.00 – $249.00; median $215.00
Analyst estimates, as of 2026-08-22. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for NBIX
- Consensus EPS estimate$2.72 next reporting period, as of 2026-08-22
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Dependence on a limited number of commercial products for the majority of revenue.","Risks associated with clinical trial success and regulatory approval processes for pipeline candidates."]
What changed in the latest 10-Q
AI-assisted comparison of NBIX's 10-Q filed 2026-05-05 against the prior one filed 2025-10-28.
Management's Discussion & Analysis (MD&A)
- Added:
- 2026 filing includes 'Business Highlights' for Q1 2026 covering net product sales increase of 43.9% to $811.0 million, Soleno Therapeutics acquisition for ~$2.9 billion announced in April 2026, sale of Neurocrine Group Limited to Immedica Pharma AB for $63.2 million completed January 21, 2026, and promotion of Andrew Ratz to Chief Technical Operations Officer
- 2026 filing includes specific Q1 2026 'Pipeline Highlights' with Phase 2 study of NBI-1117570, real-world INGREZZA vs AUSTEDO XR comparison data, tardive dyskinesia screening consensus recommendations for older adults, and two-year CRENESSITY pediatric data
- 2026 filing adds financial table for three months ended March 31, 2026 vs 2025 showing revenues, operating expenses, operating income, other income/expense, provision for taxes, and diluted earnings per share
- 2026 filing includes detailed Q1 2026 revenue breakdown: INGREZZA $656.9M, CRENESSITY $153.3M, Other $0.8M
- 2026 filing references financial statements for year ended December 31, 2025 instead of 2024
- Removed:
- 2025 filing's reference to Quarterly Report on Form 10-Q for six months ended June 30, 2025 is removed
- 2025 filing's phrase 'but few options' following 'people with great needs' is removed from company purpose statement
- 2025 filing's language stating 'neuropsychiatric, neurological, and neuroendocrine disorders' is replaced with 'neurological, psychiatric, endocrine, and immunological disorders'
- 2025 filing's phrase 'and gene therapy' is changed to 'and gene therapies'
- 2025 filing's detailed INGREZZA and CRENESSITY sales figures for nine-month periods and partnership details with MTPC/DYSVAL/REMLEAS and AbbVie/ORILISSA/ORIAHNN are removed
- 2025 filing's 'Business Highlights' covering February 2025 share repurchase program, January 2025 CMS small biotech exception notification, June 2025 CMO appointment, and planned sales team expansion are removed
- 2025 filing's extensive 2025 'Pipeline Highlights' covering Phase 3 studies for direclidine and osavampator, Phase 1 studies for NBIP-1435, NBI-921355, and NBI-1140675, KINECT-PRO Phase 4 data, SAVITRI Phase 2 data, and failed valbenazine schizophrenia Phase 3 study are removed
- Reworded:
- Company purpose changed from 'discovering and developing' to 'discovering, developing, and commercializing'
- Therapeutic area descriptions changed from 'neuropsychiatric, neurological, and neuroendocrine disorders' to 'neurological, psychiatric, endocrine, and immunological disorders'
- CAH description changed from 'classic congenital adrenal hyperplasia (CAH)' to 'classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency (CAH)'
- 'gene therapy' changed to 'gene therapies' in pipeline modalities description
- Notes:
- Older filing (2025-10-28) presents nine-month and three-month data for periods ending September 30, 2025 and 2024; newer filing (2026-05-05) presents three-month data for periods ending March 31, 2026 and 2025—these are different reporting periods and not directly comparable quarters
- Older filing contains extensive forward-looking business and pipeline information for 2025; newer filing replaces this with Q1 2026 specific information—the differences largely reflect the passage of time and new developments rather than restatements of prior periods
Risk Factors
- Added:
- Added asterisk marking to 'We may not be able to continue to successfully commercialize INGREZZA or any of our product candidates if they are approved in the future.' in the detailed risk factors section (filed 2026-05-05)
- Added phrase 'and commercialize' after 'launch' in summary risk factor bullet point (filed 2026-05-05)
- Added reference to 'products' in licensing risk factor: 'We license some of our core technologies, drug leads, products, and product candidates from third parties' (filed 2026-05-05)
- Removed:
- Removed reference to '10-K for the fiscal year ended December 31, 2024' and replaced with '10-K for the fiscal year ended December 31, 2025' (filed 2026-05-05)
- Removed specific reference to 'tardive dyskinesia' and replaced with 'TD' abbreviation (filed 2026-05-05)
- Removed specific date reference 'September 2024' and replaced with 'first quarter of 2026' for sales team expansion (filed 2026-05-05)
- Removed phrase 'and distribution capabilities' from commercial infrastructure description (filed 2026-05-05)
- Removed specific reference to 'psychiatry and long-term care' sales teams (filed 2026-05-05)
- Removed phrase 'or be forced to pay damages' and replaced with 'or be required to pay damages' in licensing risk factor (filed 2026-05-05)
- Reworded:
- Changed 'We may not be able to successfully launch CRENESSITY' to 'We may not be able to successfully launch and commercialize CRENESSITY' in summary risk factors (filed 2026-05-05)
- Changed 'drug leads and candidates' to 'drug leads, products, and product candidates' in licensing risk factor (filed 2026-05-05)
- Changed 'or be forced to pay damages' to 'or be required to pay damages' in licensing risk factor (filed 2026-05-05)
- Notes:
- The newer filing text appears truncated at the end of the CRENESSITY risk factor discussion, making a complete comparison of that section uncertain
- The older filing text also appears truncated at the same location, limiting assessment of subsequent content changes
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 23 open-market sales by insiders in the last 90 days.
- Last 30 days0 buys · 1 sell ($227508) — 1 selling insider
- Last 90 days0 buys · 23 sells ($21M) — 6 selling insiders
- Last 180 days0 buys · 27 sells ($62M) — 9 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-07-28. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about NBIX's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Congressional trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 2 matched disclosures for NBIX from U.S. House Clerk Periodic Transaction Report filings.
Congressional trading disclosures →Institutional ownership (13F)
6 institutional 13F filers reported holding NBIX as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 6
- Reported shares held 20,550,206
- Reported value $2,707,284,096
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 4 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
NBIX had 4,390,083 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
NBIX had 4.32% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 3.01 days to cover at the same settlement.
- Reported short interest (shares) 4,390,083
- Short interest (% of shares outstanding) 4.32%
- Prior settlement (shares) 5,334,688
- Reported change -17.71%
- Days to cover (reported) 3.01
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Teva Pharmaceutical Industries (TEVA)
- Acadia Pharmaceuticals (ACAD)
- AbbVie (ABBV)
- Amgen (AMGN)
- Biogen (BIIB)
- Sage Therapeutics
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare NBIX vs…
Neurocrine Biosciences is found in…
Frequently asked questions
What does Neurocrine Biosciences (NBIX) do?
Neurocrine Biosciences is a neuroscience-focused biopharmaceutical company dedicated to developing treatments for neurological, psychiatric, endocrine, and immunological disorders. The company's commercial portfolio features FDA-approved therapies for conditions such as tardive dyskinesia, Huntington's disease chorea, congenital adrenal hyperplasia, and hyperphagia in Prader-Willi syndrome. It also maintains a diverse clinical pipeline spanning small molecules, biologics, and gene therapies.
What sector is Neurocrine Biosciences (NBIX) in?
Neurocrine Biosciences (NBIX) is classified in the Health Care sector. Its industry is biopharmaceuticals. It trades on NASDAQ.
Who are Neurocrine Biosciences's (NBIX) competitors?
Notable peers of Neurocrine Biosciences (NBIX) include Teva Pharmaceutical Industries, Acadia Pharmaceuticals, AbbVie, Amgen and Biogen. This peer set is informational only — not financial advice.
Has there been recent Congressional stock trading in NBIX?
Yes — we hold 2 matched STOCK Act disclosures for NBIX from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is Neurocrine Biosciences (NBIX) overbought or oversold right now?
Neurocrine Biosciences (NBIX) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 37, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on NBIX come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.